SEC For	rm 4																		
FORM 4 UNITED ST				STAT	ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number:   3235-0287     Estimated average burden      hours per response:   0.5			
1. Name and Address of Reporting Person*    Robbins Wendye					RAPT Therapeutics, Inc. [RAPT] (Check all applied X)   X Director										r 10% Owner (give title Other (specify				
(Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC. 561 ECCLES AVENUE (Street)					Line) X Form fi										Joint/Group Filing (Check Applicable iled by One Reporting Person iled by More than One Reporting				
SOUTH SAN FRANCISCO CA 94080					Rule 10b5-1(c) Transaction Indication														
(City) (State) (Zip)								this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
Table I - Non-Deriva     1. Title of Security (Instr. 3)   2. Transa Date (Month/D)				Transac	ction 2A. Deeme Execution ay/Year) if any			ed	3. 4. Securi		of, or Benefic ities Acquired (A) od Of (D) (Instr. 3, 4		5. Amou	nt of es	Form	rm: Direct	7. Nature of Indirect Beneficial		
				(Month/Day/Ye			ay/Yea	ar) 8)	$\rightarrow$	Amount (A) or (D)		r Price	Owned Following Reported Transaction(s) (Instr. 3 and 4)		(I) (Instr. 4)		Ownership Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Da Execution Da if any (Month/Day/Y	te, Tra	4. Transaction Code (Instr.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$8.98	03/28/2024		1	•		6,925		(1)	03/2	27/2034	Common Stock	6,925	\$7.58 <sup>(2)</sup>	6,925		D		

Explanation of Responses:

1. The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2024 with the first installment vesting on March 31, 2024, provided that the reporting person is in service as a director on each such vesting date.

2. This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of \$52,500.

/s/ Rodney Young, Attorney-in-	04/01/2024
Fact	04/01/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.